Media Articles Related to Somavert (Pegvisomant)
Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Source: Endocrinology News From Medical News Today [2014.12.23]
Novartis has announced that the US Food and Drug Administration (FDA) has approved Signifor® long-acting release (LAR)* (pasireotide) for injectable suspension, for intramuscular use, for the...
Published Studies Related to Somavert (Pegvisomant)
Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. [2011.08]
CONTEXT: Cotreatment of acromegaly with pegvisomant and a somatostatin analog (SA) has proven feasible. Previous studies in the field have focused on patients with an insufficient response to SA monotherapy in whom pegvisomant was added without changing the SA dose. OBJECTIVE: The objective of the study was to study whether patients sufficiently controlled on SA monotherapy can be transferred to combination therapy with low-dose pegvisomant and a reduced SA dose... CONCLUSION: Acromegalic patients well controlled on SA monotherapy can maintain safe IGF-I levels during 24 wk of cotreatment with low-dose pegvisomant and a 50% reduced SA dose. This treatment modality, however, does not seem to provide significant benefits for the patients.
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. [2009.12]
CONCLUSIONS: Pegvisomant and octreotide LAR were equally effective in normalizing IGF-I in the overall population, and pegvisomant was more effective in patients with higher baseline IGF-I levels. Pegvisomant had a more favorable effect on parameters of glycemic control.
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. [2009.10]
OBJECTIVE: For patients with acromegaly who are suboptimally controlled on long-acting octreotide (LAR), treatment options are to switch to pegvisomant monotherapy (PM) or add pegvisomant to LAR (P-LAR). Our objective was to evaluate if the safety and efficacy of these regimens differ... CONCLUSIONS: In patients suboptimally controlled on LAR, PM and P-LAR were equally well tolerated and effective in normalizing IGF-I, and overall clinical improvement was observed with both regimens. Thus, pegvisomant monotherapy and adjunctive therapy are equally viable options for the treatment of LAR-resistant acromegaly.
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. [2008.10]
OBJECTIVE: The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment... CONCLUSION: Improvement in quality of life was observed without significant change in IGF-I after the addition of 40 mg pegvisomant weekly to monthly SSA therapy in acromegalic patients who had normalized IGF-I on SSA monotherapy. These data question the current recommendations in how to assess disease activity in acromegaly. Moreover, the findings question the validity of the current approach of medical treatment in which pegvisomant is used only when SSA therapy has failed to normalize IGF-I.
Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. [2006.08]
CONCLUSIONS: Pegvisomant effectively reduced IGF-I and IGFBP-3 levels in gsp-mediated GH excess but had no effect on fibrous dysplasia.
Clinical Trials Related to Somavert (Pegvisomant)
Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects [Not yet recruiting]
The hypothesis to be tested is that the bioavailability of the new 30-mg vial is similar to
that of the current approved 15 - mg vials. In addition, the SC injection using the new 30-mg
vial is safe and well-tolerated.
Acute Application of Pegvisomant and Octreotide in Acromegaly [Completed]
The purpose of the study is to investigate the efficacy of an acute additional application of
the somatostatin analogue octreotide 100µg s. c. or the dopamine agonist cabergoline 0. 5mg
p. o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing
endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors [Recruiting]
Pegvisomant And Sandostatin LAR Combination Study [Completed]
The purpose of this study is to compare the safety and tolerability of combination therapy
with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients [Completed]
Study Synopsis Study Title: Double blind, single centre, cross-over study on the effects of
weekly subcutaneous administration of 40 mg pegvisomant or placebo on quality of life and
insulin sensitivity in acromegalic patients with normal serum IGF-I concentrations during
long-term treatment with long-acting somatostatin analogs
1. To determine whether the addition of weekly pegvisomant administrations improves quality
2. To determine whether the addition of weekly pegvisomant administrations improves insulin
Study Population: Acromegalic patients, who have normalized their serum IGF-I levels down to
the upper 25 centiles of normality during long-term treatment with monthly injections of a
long-acting somatostatin analogue Number of Subjects: 20
- Patients on treatment with Sandostatin LAR (SL) 20 - 30 mg per months i. m. or patients
on treatment with Lanreotide autosolution (LA) 90 - 120 mg deep s. c. will be enrolled.
- For 4 months, all subjects will also receive weekly s. c. injections of either placebo or
a fixed dose of 40 mg pegvisomant
- After a 4 weeks wash-out period, patients will switch from either placebo to pegvisomant
or from pegvisomant to placebo
- Before, and after 2 and 4 months of each treatment period, serum efficacy parameters and
quality of life (AcroQol â„¢/ PASQâ„¢) will be assessed.
- Before and after 4 months of each treatment period, pituitary tumor size and insulin
sensitivity (HOMA/SIGMA model) will be assessed. Duration of study: 9 months
â€¢We postulate that co-administration of the growth hormone receptor antagonist pegvisomant
will improve QoL and insulin sensitivity
Reports of Suspected Somavert (Pegvisomant) Side Effects
Weight Increased (8),
Blood Growth Hormone Increased (7),
Drug Ineffective (6),
Hypersensitivity (5), more >>